Neurocode’s High Sensitivity p-tau217 Blood Test
Brain Risk Insights - Now In Australia
For practitioners - Learn about p-tau217, GFAP and NfL insights to support your patients.
For clients - Explore your next steps with confidence.
What Is It
For decades, Alzheimer’s risk was only recognised once symptoms appeared or after invasive, costly tests. That has changed. Today, simple blood tests can detect biological changes relating to the brain and its protection mechanisms, years decades before cognitive symptoms relating to Alzheimer’s occur. The brain risk insights panel measures three different blood markers.
High-sensitivity p-tau 217
p-tau217 is closely aligned with amyloid pathology. It is highly predictive of Alzheimer’s insights.
Glial Fibrillary Acidic Protein (GFAP)
GFAP provides insights to levels of brain inflammation and injury.
Neurofilament Light Chain (Nf-L)
Nf-L levels provide insights to nerve cell damage and neurodegeneration.
How to Order
You can order the brain risk insights panel directly via OptiLab using the link below. Cognevity does not provide or run the test.
We offer education and support sessions to help you learn about the markers, why they may be activated and what you could do next alongside your healthcare provider.
Received Your Report?
Learn about your BrainScan risk insights p-tau217, GFAP and Nf-L report.
We support you with education-based information on p-tau217, GFAP and Nf-L, why they might become activated and what you can proactively do next - there is a lot that you can do.
Practitioner Support
Cognevity works with Australia-based OptiLab as an education partner and collaborates with Neurocode the test developer.
Learn about the biomarker, when testing may be appropriate, what results can and cannot tell you, how to order the test for your patients, and how insights may support informed next steps for cognitive health and Alzheimer’s risk management.
Cognevity provides the session by Zoom with an option for in-person for larger groups that are based in Sydney.